Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature

Published:2018-12 Issue:6 Volume:28 Page:491-501
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Zhao Cathy Yunjia,Hwang Shelley Ji Eun,Consuegra Germana,Chou Shaun,Fernandez-Peñas Pablo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference40 articles.

1. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

2. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab;McDermott;J Clin Oncol,2015

3. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer;Gettinger;J Clin Oncol,2015

4. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort;Hwang;J Am Acad Dermatol,2016

5. The PD-1 pathway in tolerance and autoimmunity;Francisco;Immunol Rev,2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitor‐induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications;The Journal of Dermatology;2023-11-30

2. Comparisons of Nonoral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles;The Oncologist;2023-10-24

3. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid;Frontiers in Oncology;2023-03-03

4. A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy;Biomedicines;2023-01-24

5. Lichenoid drug reaction after ipilimumab/nivolumab combination therapy: A case report;SAGE Open Medical Case Reports;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3